ArticleCureus2025
Posterior Reversible Encephalopathy Syndrome: A Case Report With Contemporary Literature Review and Neuropathological Evidence From Autopsy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a neuro-radiological condition characterized by vasogenic edema in the parieto-occipital brain regions. Although typically reversible, some cases result in irreversible damage, particularly with delayed treatment. This study reviews 12 autopsy-confirmed cases and presents a novel case, emphasizing neuropathological findings that challenge the assumption of reversibility. Common pathological features include white matter edema, axonal swelling, and fibrinoid necrosis. Risk factors for PRES include hypertension (HTN), autoimmune diseases, renal failure, immunosuppressive therapies, and organ transplantation. Clinical presentations range from headaches and seizures to coma, while MRI often shows T2 hyperintensities in posterior brain regions, which may resolve in follow-up imaging. Electroencephalogram (EEG) in the presented case demonstrated moderate diffuse slowing and some focal abnormalities, suggestive of cerebral dysfunction related to PRES. This novel case involves a 27-year-old homeless African American woman with a history of autoimmune disease, who presented with pain, weight loss, and weakness. Initial findings included elevated inflammatory markers and antibodies, leading to diagnoses of polymyositis, kidney injury, and pericardial effusion. During hospitalization, she experienced seizures and was suspected of having anti-NMDA (anti-N-methyl-D-aspartate) receptor encephalitis, for which she received IV immunoglobulins. MRI findings aligned with PRES. Despite interventions, including plasma exchange and rituximab therapy, she experienced cardiac arrest and ultimately passed away. Autopsy data provides crucial insights into the progression of PRES, emphasizing the importance of prompt diagnosis and treatment to prevent irreversible damage and fatal complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.